Literature DB >> 15143155

17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter.

Jill Adamski1, Zhendong Ma, Susan Nozell, Etty N Benveniste.   

Abstract

Major histocompatibility complex (MHC) class II proteins are important for the initiation of immune responses and are essential for specific recognition of foreign antigens by the immune system. Regulation of class II MHC expression primarily occurs at the transcriptional level. The class II transactivator protein is the master regulator that is essential for both constitutive and interferon-gamma-inducible class II MHC expression. Estrogen [17beta-estradiol (17beta-E2)] has been shown to have immunomodulatory effects. In this study, we show that 17beta-E2 down-regulates interferon-gamma inducible class II MHC protein levels on brain endothelial cells, as well as other cell types (astrocytes, fibrosacroma cells, macrophages). The inhibitory effects of 17beta-E2 on class II MHC expression are not due to changes in class II transactivator mRNA or protein levels, rather, 17beta-E2 mediates inhibition at the level of class II MHC gene expression. We demonstrate that 17beta-E2 attenuates H3 and H4 histone acetylation and cAMP response element binding protein-binding protein association with the class II MHC promoter, suggesting that 17beta-E2 inhibits class II MHC expression by a novel mechanism involving modification of the histone acetylation status of the class II MHC promoter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143155     DOI: 10.1210/me.2004-0098

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  17 in total

Review 1.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

2.  Interactions between the immune system and bone.

Authors:  Patrizia D'Amelio; Giorgia Fornelli; Ilaria Roato; Giovanni Carlo Isaia
Journal:  World J Orthop       Date:  2011-03-18

Review 3.  The immune system and bone.

Authors:  Roberto Pacifici
Journal:  Arch Biochem Biophys       Date:  2010-06-17       Impact factor: 4.013

Review 4.  Multiple sclerosis; a disease of reproductive-aged women and the dilemma involving contraceptive methods.

Authors:  Esengül Türkyılmaz; Melahat Yıldırım; Ayşe Filiz Yavuz Avşar
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

Review 5.  Immune modulation by estrogens: role in CNS HIV-1 infection.

Authors:  Melinda E Wilson; Filomena O Dimayuga; Janelle L Reed; Thomas E Curry; Carol F Anderson; Avindra Nath; Annadora J Bruce-Keller
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

6.  Effect of oestradiol and pathogen-associated molecular patterns on class II-mediated antigen presentation and immunomodulatory molecule expression in the mouse female reproductive tract.

Authors:  Daniel O Ochiel; Richard M Rossoll; Todd M Schaefer; Charles R Wira
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

Review 7.  Estrogen deficiency and bone loss: an inflammatory tale.

Authors:  M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1.

Authors:  Olivia I Koues; R Kyle Dudley; Agnieszka D Truax; Dawson Gerhardt; Kavita P Bhat; Sam McNeal; Susanna F Greer
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

Review 9.  Regulation of major histocompatibility complex class II gene expression, genetic variation and disease.

Authors:  L Handunnetthi; S V Ramagopalan; G C Ebers; J C Knight
Journal:  Genes Immun       Date:  2009-11-05       Impact factor: 2.676

10.  Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis.

Authors:  Bruce F Bebo; Babak Dehghani; Scott Foster; Astrid Kurniawan; Francisco J Lopez; Larry S Sherman
Journal:  Glia       Date:  2009-05       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.